Improvements and Limitations of Humanized Mouse M "Meet the Experts†2015 Workshop Summary

AIDS Research and Human Retroviruses 32, 109-119

DOI: 10.1089/aid.2015.0258

Citation Report

#	Article	IF	CITATIONS
1	Immune-competent human skin disease models. Drug Discovery Today, 2016, 21, 1479-1488.	3.2	39
2	Improving combination antiretroviral therapy by targeting HIV-1 gene transcription. Expert Opinion on Therapeutic Targets, 2016, 20, 1311-1324.	1.5	13
3	HIV-associated neurocognitive disorder â€" pathogenesis and prospects for treatment. Nature Reviews Neurology, 2016, 12, 234-248.	4.9	690
4	Human Effector Memory T Helper Cells Engage with Mouse Macrophages and Cause Graft-versus-Host–Like Pathology in Skin of Humanized Mice Used in a Nonclinical Immunization Study. American Journal of Pathology, 2017, 187, 1380-1398.	1.9	23
5	Tackling HIV and AIDS: contributions by non-human primate models. Lab Animal, 2017, 46, 259-270.	0.2	25
6	Chimeric antigen receptor engineered stem cells: a novel HIV therapy. Immunotherapy, 2017, 9, 401-410.	1.0	17
7	Humanized Mouse Models of Clinical Disease. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 187-215.	9.6	437
8	Humanized Mouse Models for Human Immunodeficiency Virus Infection. Annual Review of Virology, 2017, 4, 393-412.	3.0	65
9	Humanized mouse models of latent HIV infection. Current Opinion in Virology, 2017, 25, 97-104.	2.6	14
10	Tracking Human Immunodeficiency Virus-1 Infection in the Humanized DRAG Mouse Model. Frontiers in Immunology, 2017, 8, 1405.	2.2	28
11	Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice. PLoS ONE, 2017, 12, e0183425.	1.1	15
12	HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. Journal of Virology, 2018, 92, .	1.5	36
13	From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E802-E811.	3.3	30
14	Isolation of human lymphocytes with high yield and viability from the gastrointestinal and female reproductive tract of a humanized DRAG mouse. Journal of Immunological Methods, 2018, 454, 40-47.	0.6	1
15	Humanized mouse models infected with human <i>Plasmodium</i> species for antimalarial drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 131-140.	2.5	7
16	Ultra-Sensitive HIV-1 Latency Viral Outgrowth Assays Using Humanized Mice. Frontiers in Immunology, 2018, 9, 344.	2.2	16
17	Human Immune System Mice for the Study of Human Immunodeficiency Virus-Type 1 Infection of the Central Nervous System. Frontiers in Immunology, 2018, 9, 649.	2.2	2
18	The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer. Frontiers in Immunology, 2018, 9, 746.	2.2	31

#	Article	IF	Citations
19	Epigenetics, N-myrystoyltransferase-1 and casein kinase-2-alpha modulates the increased replication of HIV-1 CRF02_AG, compared to subtype-B viruses. Scientific Reports, 2019, 9, 10689.	1.6	4
20	Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nature Communications, 2019, 10, 2753.	5.8	222
21	Humanized mouse models of immunological diseases and precision medicine. Mammalian Genome, 2019, 30, 123-142.	1.0	76
22	Enhanced Transduction of Macaca fascicularis Hematopoietic Cells with Chimeric Lentiviral Vectors. Human Gene Therapy, 2019, 30, 1306-1323.	1.4	3
23	Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice. Frontiers in Immunology, 2019, 10, 340.	2.2	20
24	Recent Updates on Mouse Models for Human Immunodeficiency, Influenza, and Dengue Viral Infections. Viruses, 2019, 11, 252.	1.5	22
25	Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized mice. PLoS Pathogens, 2019, 15, e1008161.	2.1	19
26	Lack of acute xenogeneic graftâ€∢i>versusà€host disease, but retention of Tâ€cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB Journal, 2019, 33, 3137-3151.	0.2	99
27	Accelerating HIV vaccine development using non-human primate models. Expert Review of Vaccines, 2019, 18, 61-73.	2.0	16
28	HIV-Associated Neurocognitive Disorder (HAND): Relative Risk Factors. Current Topics in Behavioral Neurosciences, 2020, 50, 401-426.	0.8	9
29	Mimicking SIV chimpanzee viral evolution toward HIVâ€1 during crossâ€species transmission. Journal of Medical Primatology, 2020, 49, 284-287.	0.3	5
30	Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop. Current HIV Research, 2020, 18, 19-28.	0.2	9
31	Bibliometric analysis of personalized humanized mouse and Drosophila models for effective combinational therapy in cancer patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165880.	1.8	5
32	Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice. Trends in Immunology, 2020, 41, 706-720.	2.9	23
33	The Utility of Human Immune System Mice for High-Containment Viral Hemorrhagic Fever Research. Vaccines, 2020, 8, 98.	2.1	4
34	Broadly Neutralizing Antibodies for HIV Prevention. Annual Review of Medicine, 2020, 71, 329-346.	5.0	49
35	Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development. ACS Pharmacology and Translational Science, 2021, 4, 213-225.	2.5	14
36	Mouse Models of the Humanized Immune System. , 2021, , 725-742.		0

#	Article	IF	CITATIONS
37	A humanized CD3 $\hat{l}\mu$ -knock-in mouse model for pre-clinical testing of anti-human CD3 therapy. PLoS ONE, 2021, 16, e0245917.	1.1	3
39	Humanized Mice for Infectious and Neurodegenerative disorders. Retrovirology, 2021, 18, 13.	0.9	20
40	Broadly Neutralizing Antibodies for HIV-1 Prevention. Frontiers in Immunology, 2021, 12, 712122.	2.2	43
41	Modular Approaches to Understand the Immunobiology of Human Immunodeficiency Virus Latency. Viral Immunology, 2021, 34, 365-375.	0.6	1
42	Neonatal microcephaly and humanized mouse models for Zika viral pathogenesis and immunity. , 2021, , 429-437.		1
43	Chemoattractant-mediated leukocyte trafficking enables HIV dissemination from the genital mucosa. JCI Insight, 2017, 2, e88533.	2.3	15
45	Evolution of SIVsm in humanized mice towards HIVâ€2. Journal of Medical Primatology, 2020, 49, 280-283.	0.3	5
46	Novel Humanized Peripheral Blood Mononuclear Cell Mouse Model with Delayed Onset of Graft-versus-Host Disease for Preclinical HIV Research. Journal of Virology, 2022, 96, JVI0139421.	1.5	11
47	Current Status, Barriers, and Future Directions for Humanized Mouse Models to Evaluate Stem Cell–Based Islet Cell Transplant. Advances in Experimental Medicine and Biology, 2022, , 89-106.	0.8	1
49	Engineered induced-pluripotent stem cell derived monocyte extracellular vesicles alter inflammation in HIV humanized mice., 2022, 3, 118-32.		2
50	Humanized mouse models for preclinical evaluation of HIV cure strategies. AIDS Reviews, 2022, 24, .	0.5	2
51	Advancing Key Gaps in the Knowledge of Plasmodium vivax Cryptic Infections Using Humanized Mouse Models and Organs-on-Chips. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3
52	Golden Syrian Hamster Models for Cancer Research. Cells, 2022, 11, 2395.	1.8	7
53	Longâ€ŧerm evolutionary adaptation of <scp>SIVcpz</scp> toward <scp>HIV</scp> â€1 using a humanized mouse model. Journal of Medical Primatology, 2022, 51, 288-291.	0.3	3
54	Animal models for studies of HIV-1 brain reservoirs. Journal of Leukocyte Biology, 2022, 112, 1285-1295.	1.5	11
55	Humanized mouse models for immuno-oncology research. Nature Reviews Clinical Oncology, 2023, 20, 192-206.	12.5	54

HIV-1 transmission: modelling and direct visualization in the third dimension. Microscopy (Oxford,) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50